Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tao Synergies Inc. (TAOX : NSDQ)
 
 • Company Description   
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.53 Daily Weekly Monthly
20 Day Moving Average: 162,654 shares
Shares Outstanding: 7.47 (millions)
Market Capitalization: $33.85 (millions)
Beta: 1.49
52 Week High: $11.98
52 Week Low: $2.12
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.87% -16.17%
12 Week 8.63% 0.43%
Year To Date 23.10% 17.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1185 Avenue of the Americas 3rd Floor
-
New York,NY 10036
USA
ph: 973-242-0005
fax: -
ir@taosynergies.com http://www.taosynergies.com
 
 • General Corporate Information   
Officers
Joshua N. Silverman - Executive Chairman and Director
Bruce T. Bernstein - Vice-Chairman
Robert Weinstein - Chief Financial Officer; Secretary and Executive V
William S. Singer - Director
Robert Ephron - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: FIN-MISC SVCS
Sector: Finance
CUSIP: 87167T300
SIC: 6199
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/21/26
Share - Related Items
Shares Outstanding: 7.47
Most Recent Split Date: 4.00 (0.04:1)
Beta: 1.49
Market Capitalization: $33.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/21/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.46
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -1,250.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 322.65%
ROE
03/31/26 - -163.40
12/31/25 - -193.08
09/30/25 - -240.92
ROA
03/31/26 - -133.47
12/31/25 - -144.93
09/30/25 - -150.03
Current Ratio
03/31/26 - 27.39
12/31/25 - 13.99
09/30/25 - 17.61
Quick Ratio
03/31/26 - 27.39
12/31/25 - 13.99
09/30/25 - 17.61
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -3,635.47
12/31/25 - -9,611.04
09/30/25 - -13,103.94
Book Value
03/31/26 - 3.11
12/31/25 - 2.83
09/30/25 - 3.55
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©